Anti‐Thymocyte Globulin as a Therapy for Chronic Lung Allograft Dysfunction: A Single‐Center Experience
Anti-thymocyte globulin therapy, when given for CLAD, was associated with at least a modest attenuation in rate of FEV1 decline in most patients but only rarely preceded an absolute improvement in FEV1. Further study is warranted to better define the role for ATG in treatment of CLAD, a challenging disease state with limited therapeutics available.
Authors
- Manish Mohanka
- Ang Gao (ORCID: https://orcid.org/0000-0002-9513-9114)
- Vaidehi Kaza (ORCID: https://orcid.org/0000-0003-3578-6077)
- Lynn C. Huffman
- Christopher Heid
- Adrian Lawrence
- Matthias Peltz (ORCID: https://orcid.org/0000-0002-7384-252X)
- J. Murala (ORCID: https://orcid.org/0000-0001-6782-9188)
- Colin Dunn (ORCID: https://orcid.org/0000-0001-7739-2805)
- Suresh Keshavamurthy (ORCID: https://orcid.org/0000-0002-5578-1911)
- Song Zhang (ORCID: https://orcid.org/0000-0002-1263-6693)
- Fernando Torres (ORCID: https://orcid.org/0000-0002-9587-010X)
- I. Timofte
- Steve Ring
- A. N. Jacob
- William Brandon
- Michael Alton Wait
- Srinivas Bollineni
- Alex Jaye Weston
Institutions
- Southwestern Medical Center (US)
- Southwestern Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Clinical Transplantation
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1111/ctr.15461
- Citations
- 1
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.57